Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Slides:

Advertisements

Similar presentations

A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.

Advertisements

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

LUX-Lung 6 clinical trial

LUX-Lung 3 clinical trial

Gajria D et al. Proc SABCS 2010;Abstract P

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Robert Klein, MS, Catherine.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

UK ABC-02 trial: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter,

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 3 Proportion of patients for whom NEDA

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Care needs of patients with advanced-stage cancer

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment of Stage IV Non-small Cell Lung Cancer

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Figure 2 Frequency and overlap of alterations

Practical Guidance on the Management of Pan-Negative NSCLC

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Journal of Thoracic Oncology

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Figure 3 Determination of the primary site

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer Giorgio.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial. In this phase III randomized controlled trial, relative efficacies of chemotherapy (cisplatin plus gemcitabine) versus erlotinib as first-line treatments of patients with advanced-stage non-small-cell lung cancer were investigated. These data suggest that physicians are more accurate in reporting adverse effects that are expected with each specific treatment — nausea and vomiting with cisplatin plus gemcitabine, and diarrhoea with erlotinib25. Di. Maio, M. et al. (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.222